From PharmD to Ph.D., Kwame Adjei is Research-Laden

May 08, 2025
Pharmacy Admin

Kwame Adjei in front of rattler statue

Tallahassee, FL - Recipient of a PharmD from Kwame Nkrumah University of Science and Technology in Kumasi, Ghana, West Africa Home | Kwame Nkrumah University of Science and Technology Kwame Adjei began his Ph.D. studies in Fall 2020 at the FAMU CoPPS, IPH’s Economic, Social and Administrative Pharmacy, studying remotely from Ghana due to COVID-19 before transitioning to in-person learning in 2021. His research focused on healthcare efficiency and policy, culminating in a dissertation defended in March 2025 that evaluated the cost-effectiveness and Real Option Value (ROV) of Gefitinib/Erlotinib versus Osimertinib for advanced NSCLC (Non-Small Cell Lung Cancer). His findings showed that while Osimertinib may not be cost-effective under traditional methods, it becomes favorable when ROV is considered—highlighting the importance of dynamic value assessment in oncology decision-making. These insights have significant implications for clinical guidelines and global health policy. He expressed gratitude to his major professor, Dr. Askal Ali, along with his committee, and the entire FAMU family (FAMUly) for the support and guidance throughout his doctoral journey.

Dr. Adjei
Dr. Adjei

When asked, he humbly provided a “Quote of Hope”—"My journey at Florida A&M University has been a testament to the power of faith, resilience, and the transformative value of education. As I step into this new chapter of my life, I carry the legacy of FAMU’s excellence and the unwavering belief that future scholars—especially those from underrepresented backgrounds—can dream boldly, break barriers, and know they belong at the forefront of innovation.”  –Kwame Adjei, PharmD, Ph.D.

With his options, he's decided upon a post-doctoral experience at Johnson & Johnson: Changing health for humanity and beyond his dissertation’s research, Dr. Adjei/Kwame’s work advances evidence-based care and resource optimization in healthcare systems. He held leadership roles in ISPOR’s student network and completed health economics internships at EMD Serono (2023) and AbbVie (2024).

Striking with intention, Dr. Adjei has collaborated with clinicians, data scientists, and industry experts, contributing to high-impact publications on mental health, antidepressant utilization, and glaucoma treatment. Now, with the pursuit of a Johnson & Johnson pharmaceutical postdoctoral fellowship, Dr. Adjei continues his commitment to impactful, policy-relevant research in health economics and outcomes. His research has been featured in high-impact journals, including:



CATEGORIES